Two Treatments For IPF Edge Closer To Market, Will Come Down To Subtle Differences
This article was originally published in Pharmaceutical Approvals Monthly
InterMune’s pirfenidone and Boehringer Ingelheim’s nintedanib are neck-and-neck in the race to be the first drug interventions in the U.S. for the fatal lung disease. Phase III data from both drugs were presented at the American Thoracic Society meeting and published in the NEJM May 18.
You may also be interested in...
Pulmonary Fibrosis Patients Talk Quality Of Life More Than Potential New Treatments
FDA patient-focused drug development meeting on IPF mostly addresses ways to cope with symptoms.
Compassionate Use Questions Could Arise At FDA/Patient Meeting On IPF Treatments
InterMune already has made its pirfenidone available to idiopathic pulmonary fibrosis patients on a compassionate-use basis.
ASCEND Data Puts InterMune’s Pirfenidone On Top
Phase III trial of idiopathic pulmonary fibrosis drug puts company in strong position for FDA approval of first treatment for orphan disease and strong reimbursement in U.S. and abroad.